Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance
Authors:
Open Access
- 30 September 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 21 (1) , 121-128
Abstract
BACKGROUND: Few studies have evaluated insulin sensitizers in comparison/association with oral contraceptives (OC) in women with polycystic ovary syndrome (PCOS) with insulin resistance (IR). This study assessed the effects of a thiazolidinedione versus an anti-androgenic estrogen–progestin followed by their sequential combinations in overweight PCOS women. METHODS AND RESULTS: Twenty-eight candidates in whom elevated insulin was not normalized after 4 months of diet were randomly assigned to 6 months of rosiglitazone 4 mg/day or to ethinyl estradiol 35 mg/cyproterone acetate 2 mg (EE/CPA: 21/28 days cycle). Each group then received both medications for another 6 months. Rosiglitazone reduced insulin, IR indices [homeostasis model assessment (HOMA) and quantitative sensitivity check index (QUICKI)] and the insulin area under the curve in response to an oral glucose tolerance test (OGTT), but had limited effect on lipids, androgens and hirsutism. EE/CPA did not modify insulin and OGTT response but increased high-density lipoprotein cholesterol and triglycerides and decreased androgens and hirsutism. Similar changes occurred during combined treatments. End results were highly significant in combined groups without noticeable side-effects or changes in safety parameters. CONCLUSIONS: In obese PCOS women with high insulin not corrected by diet, the combination of rosiglitazone and EE/CPA may be used to achieve complementary beneficial effects on endocrine–metabolic anomalies and clinical symptoms.Keywords
This publication has 41 references indexed in Scilit:
- The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patientsHuman Reproduction, 2005
- Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndromeFertility and Sterility, 2004
- Effect of the Insulin Sensitizer Pioglitazone on Insulin Resistance, Hyperandrogenism, and Ovulatory Dysfunction in Women with Polycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism, 2004
- Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndromeFertility and Sterility, 2004
- Ultrasound assessment of the polycystic ovary: international consensus definitionsHuman Reproduction Update, 2003
- Glucose Metabolism and Insulin Resistance in Women with Polycystic Ovary Syndrome during Therapy with Oral Contraceptives Containing Cyproterone Acetate or DesogestrelThe Journal of Clinical Endocrinology & Metabolism, 2003
- Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic PatientsObesity Research, 2002
- Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled TrialThe Journal of Clinical Endocrinology & Metabolism, 2001
- Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.Diabetes, 2000
- Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndromeMetabolism, 1995